Source - RNS
RNS Number : 9502L
AstraZeneca PLC
07 October 2016
 

 

This announcement contains inside information

 

7 October 2016 07:00

 

ASTRAZENECA ENTERS AGREEMENT WITH

CILAG GMBH INTERNATIONAL TO DIVEST RIGHTS TO RHINOCORT AQUA
OUTSIDE THE US

 

AstraZeneca today announced that it has entered into an agreement with Cilag GmbH International, an affiliate of Johnson & Johnson, for the divestment of the rights to Rhinocort Aqua outside the US.

 

Rhinocort Aqua is a nasal spray indicated for allergic and non-allergic rhinitis (inflammation of the inside of the nose), and for the treatment of nasal polyps (swelling of the nasal lining). The active ingredient is the anti-inflammatory medicine budesonide.

 

Mark Mallon, Executive Vice President, Global Product & Portfolio Strategy at AstraZeneca, said: "This agreement allows us to concentrate our efforts in Respiratory as one of our three strategic therapy areas, on transforming the treatment of asthma and COPD, where budesonide remains a key component of our marketed as well as pipeline medicines."

 

Financial considerations

The agreement is subject to customary closing conditions and is expected to complete in the fourth quarter of 2016. As AstraZeneca will not maintain a significant ongoing interest in Rhinocort Aqua, the $330 million payment received from Cilag GmbH International upon completion of the transaction will be recognised as Other Operating Income in the Company's financial statements. The transaction does not include the transfer of any AstraZeneca employees or facilities and does not impact the Company's financial guidance for 2016.

 

About AstraZeneca

AstraZeneca is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Respiratory, Cardiovascular & Metabolic Diseases, and Oncology. The Company is also selectively active in Neuroscience and Autoimmunity. AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. For more information please visit: www.astrazeneca.com

 

CONTACTS

 

Media Enquiries

 

 

 

 

 

Neil Burrows

 

UK/Global

 

+44 203 749 5637

 

Vanessa Rhodes

 

UK/Global

 

+44 203 749 5736

 

Karen Birmingham

 

UK/Global

 

+44 203 749 5634

 

Rob Skelding

 

UK/Global

 

+44 203 749 5821

 

Jacob Lund

 

Sweden

 

+46 8 553 260 20

 

Michele Meixell

 

US

 

+1 302 885 2677

 

Investor Relations



UK



Thomas Kudsk Larsen

 

 

 

+44 203 749 5712

 

Craig Marks

 

Finance, Fixed Income, M&A

 

+44 7881 615 764

 

Nick Stone

 

Respiratory

 

+44 203 749 5716

 

Henry Wheeler

 

Oncology

 

+44 203 749 5797

 

Christer Gruvris

Neuroscience & Autoimmunity

+44 203 749 5711

US



Lindsey Trickett

 

Cardiovascular & Metabolic Diseases

 

+1 240 543 7970

 

Mitchell Chan

 

 Oncology

 

+1 240 477 3771

 

Toll-free


+1 866 381 7277

 

Adrian Kemp

Company Secretary

AstraZeneca PLC

 

-ENDS-

 


This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
AGRAKADKNBDBBKK

Related Charts

AstraZeneca (AZN)

+164.25p (+3.99%)
delayed 18:15PM